Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Matrix metalloprotease (MMP-13) was cloned from breast cancer cells in 1994 and has important bone biological roles in the development of cartilage tissue growth and calcification centers. MMP-13 is the main enzyme that promotes its degradation, which irreversibly degrades type II collagen, causing destruction of articular cartilage. MMP-13 can be affected by a variety of factors, such as IL1β, TNF-α, Runx2. The can induce the expression of MMP-13. Hypomethylation of the MMP-13 promoter region also induces its expression, but its expression can be reduced by inhibiting histone acetylation. In addition, microRNAs can also reduce MMP-13 expression through gene regulation. Up-regulation of MMP-13 causes degeneration of cartilage, which in turn promotes the progression of arthritis.
Figure 1. Regulatory network of MMP-13 in OA chondrocytes. (Li, H., et al. 2017)
MMP-13 and Osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis, usually characterized by joint pain and dysfunction, which seriously affects the quality of life of patients. MMP-13 can preferentially degrade type II collagen to make it a major protease for cartilage degradation. In addition, it can degrade proteoglycans, type IV and type IX collagen, osteonectin and cartilage basement glycans, which are also components of the cartilage matrix. MMP-13 is rarely seen in normal adult tissues, but is more expressed in articular cartilage of OA patients. Compared with other MMPs, MMP-13 expression is more confined in connective tissue. Clinical studies have found that MMP-13 is highly expressed in patients with articular cartilage destruction, suggesting that increased MMP-13 may be associated with cartilage degradation. Studies have also found that transgenic mice overexpressing MMP-13 show a spontaneous OA-like articular cartilage degradation phenotype, while MMP-13 gene knockout prevents joint cartilage degradation.
Studies have found that down-regulation of MMP-13 expression may alter phenotype in mice deficient in fibroblasts. Studies have shown that up-regulation of MMP-13 transcription can affect cartilage homeostasis, leading to joint disease, while down-regulation of MMP-13 expression and activation can achieve therapeutic OA. The intrinsic Smad3 gene of chondrocytes maintains articular cartilage by inhibiting the expression of Runx-2-inducible MMP-13, preventing OA production. Studies have found that selective MMP-13 inhibitors completely inhibit the degradation of type II collagen in bovine knee joint grafts and inhibit the degradation of 80% of human OA cartilage. Moreover, a study has shown that MMP-13 inhibitors are effective in reducing articular cartilage loss in a wound-mediated knee OA mouse model. The study also found that some inhibitors that do not act on MMP-13 itself. For example, the purchase of Juni (vitamin) can be used to inhibit MMP-13 by inhibiting the induction and activation of MMP -13 gene levels by IL-1β.
MMP-13 and Periodontitis
MMP-13 is closely related to the rapid transformation of collagen fibers in tissues. Since MMP-13 is the primary expression of collagenase in epithelial tissues, it is also expressed in inflammatory periodontal connective tissue cells. Therefore, MMP-13 plays an important role in the transformation of epithelial tissue into connective tissue in the presence of oral mucosal inflammation. Studies have shown that the quality of collagenase and gelase in gingival crevicular fluid (GCF) is positively correlated with the severity of periodontal disease, while MMP-8 and 9 play a leading role in chronic periodontitis. In contrast, MMP-13 accounts for only 3% to 4% of the same type of inflammatory GCF, while MMP-1 is basically absent. However, some studies have found that human osteoblasts produce MMP-13 instead of MMP-8. MMP-13 activates osteoblasts to produce precursor MMP-9, which mediates a series of periodontal tissue destruction by MMP-8 and MMP-9.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.